Extension Study of Talampanel for Amyotrophic Lateral Sclerosis
- Study Title
- Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- Teva Identifier
- ALS-TAL-201-OL
- ClinicalTrials.gov Identifier
- NCT00982150
- Study Status
- Terminated
- Trial Condition(s)
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: Talampanel
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 80 Years
- Trial Duration
- 09/01/2009 - 06/01/2010
- Phase
- Phase 2
